Construction starts for Sartorius' new Cell Culture Technology Centre
Ground-breaking ceremony for Sartorius Stedim Cellca.
The 30-million-euro investment will accommodate the growing needs of customers.
Sartorius Stedim Cellca is building a new 30-million-euro Cell Culture Technology Center at Science Park III in Eselsberg situated at the northwestern scientific hub of the city of Ulm, Germany. Hugo de Wit, Managing Director, and Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius AG, symbolically broke ground in the presence of around 100 guests, marking the official start of construction work. “This is a significant step for Sartorius Stedim Cellca and our staff to soon be able to work in an advanced new complex. We are very proud of this as the new, modern facility will enable us to continue accommodating the growing needs of our customers in the future as well,” said de Wit.
So far, Sartorius Stedim Cellca has been working in a rented building in Laupheim. The new laboratory and office complex will approximately double the company’s space and is scheduled to be completed by the end of 2019. In addition, relocation to this zone will provide closer proximity to universities and research institutes that are based in Ulm’s Science Park. In addition, this move to the new facility, which is conveniently accessible by various transportation routes between the large cities of Stuttgart and Munich, will make it even easier for international customers to visit the company. Sartorius Stedim Cellca purchased the property of more than 6,000 m2 at Science Park III back in November 2016 and can, therefore, expand its Cell Culture Technology Center by a further 5,000 m2 as needed.
Sartorius Stedim Cellca develops cell lines and protein production processes, licenses technologies for the production of proteins and offers cell culture media. The company has been a part of the biopharma equipment supplier Sartorius Stedim Biotech since 2015 and currently employs around 90 people. Over the medium term, the company plans to extend its workforce to more than 120 people.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...